Glucos Viaflo Baxter (Glucose)

Glucos Viaflo Baxter is indicated for several clinical situations where rapid carbohydrate delivery or fluid replacement is required.

• Treatment of hypoglycemia in patients unable to take oral glucose.
• Component of parenteral nutrition regimens for patients receiving total or supplemental intravenous feeding.
• Fluid and electrolyte replacement in perioperative or trauma settings.
• Expansion of intravascular volume as an osmotic agent in resuscitation.
• Support of metabolic needs during prolonged fasting or critical illness.

Adverse reactions to Glucos Viaflo Baxter are generally related to its osmotic and metabolic properties, and they can vary in frequency and severity, ranging from mild metabolic changes to serious systemic events.

Common

• Mild hyperglycemia or temporary rise in blood glucose levels.
• Local irritation, redness, or pain at the infusion site.
• Nausea, mild gastrointestinal discomfort, or transient vomiting.
• Small electrolyte shifts such as mild hyponatremia or slight potassium changes.

Serious

• Severe hyperglycemia requiring insulin therapy.
• Fluid overload with risk of pulmonary edema or congestive heart failure.
• Allergic reactions, including rash, itching, or anaphylaxis.
• Metabolic acidosis in patients with renal impairment or severe liver disease.

When using Glucos Viaflo Baxter, clinicians should assess patient-specific factors and monitor for potential complications associated with intravenous glucose administration.

• Verify blood glucose levels before and during infusion to avoid hyper- or hypoglycemia.
• Assess fluid status and cardiac function to prevent volume overload.
• Adjust dosage in patients with renal or hepatic impairment due to altered glucose metabolism.
• Monitor electrolytes, especially sodium and potassium, for shifts related to osmotic effects.
• Use caution in patients with known allergies to formulation components or excipients.

Glucos Viaflo Baxter may interact with other agents that affect glucose metabolism, fluid balance, or electrolyte homeostasis, requiring careful consideration during co‑administration.

Avoid

• Co‑administration with high‑dose insulin or other potent hypoglycemic agents without adjusting glucose infusion rates.
• Simultaneous rapid infusion of large volumes of other crystalloids that could exacerbate fluid overload.

Use with caution

• Concurrent use of diuretics, which may amplify electrolyte disturbances.
• Administration alongside catecholamines or glucocorticoids that increase endogenous glucose production.
• Use with renal replacement therapies, as glucose clearance may be altered.
• Caution when combined with parenteral nutrition solutions containing other carbohydrates to avoid excessive total caloric load.